

DAFTAR ISI

| | Halaman |
|---|---------|
| Sampul Depan | i |
| Sampul Dalam..... | ii |
| Halaman Prasyarat Gelar | iii |
| Halaman Persetujuan..... | iv |
| Halaman Penetapan Panitia Penguji..... | v |
| Halaman Pernyataan..... | vi |
| Halaman Ucapan Terimakasih..... | vii |
| Halaman Ringkasan..... | viii |
| Halaman Summary..... | x |
| Halaman Abstrak..... | xii |
| Halaman Abstract..... | xiii |
| Daftar Isi | xiv |
| Daftar Tabel | xvii |
| Daftar Gambar | xviii |
| Daftar Singkatan dan Istilah | xix |
| Daftar Lampiran..... | xxii |
| | |
| BAB 1 PENDAHULUAN | |
| 1.1 Latar Belakang | 1 |
| 1.2 Rumusan Masalah | 4 |
| 1.3 Tujuan Penelitian | 4 |
| 1.4 Manfaat Penelitian | 5 |
| | |
| BAB 2 TINJAUAN PUSTAKA | |
| 2.1 Mikrobiota Usus | 6 |
| 2.1.1 Komposisi mikrobiota usus | 7 |
| 2.1.2 Disbiosis | 9 |
| 2.2 Hiperlipidemia..... | 10 |
| 2.2.1 Definisi | 10 |
| 2.2.2 Epidemiologi | 10 |
| 2.2.3 Hiperlipidemia dan obesitas | 11 |
| 2.2.4 Hiperlipidemia dan NAFLD..... | 13 |
| 2.2.5 Hiperlipidemia dan sindrom metabolik..... | 15 |
| 2.3 Komposisi diet..... | 17 |
| 2.3.1 Diet tinggi lemak | 17 |
| 2.3.2 Diet standar..... | 18 |
| 2.4 Peran Mikrobiota Usus dan Asam Lemak Bebas dalam Peradangan Kronis Tingkat Rendah (<i>Low Grade Inflammation</i>) Terkait Obesitas..... | 19 |
| 2.4.1 Perubahan komposisi mikrobiota usus | 20 |
| 2.4.2 Sekresi asam lemak bebas | 22 |

| | | |
|-------|--|----|
| 2.5 | Permeabilitas usus, Lipopolisakarida (LPS), dan <i>Monocyte chemotatic protein-1</i> (MCP-1) | 25 |
| 2.6 | Sistem Imun | 29 |
| 2.6.1 | Sistem imun <i>innate</i> (bawaan) | 29 |
| 2.6.2 | Sistem imun adaptif..... | 32 |
| 2.7 | Jalur Pensinyalan IL8 | 35 |
| 2.7.1 | Jalur tergantung pada MyD88 | 36 |
| 2.7.2 | Jalur tergantung pada TRIF..... | 37 |
| 2.8 | Peran Probiotik <i>Lactobacillus plantarum</i> | 37 |
| 2.8.1 | Sebagai antihiperlipidemia melalui garam empedu | 37 |
| 2.8.2 | Sebagai anti inflamasi | 42 |
| 2.9 | Cara pembuatan <i>Lactobacillus plantarum</i> | 49 |
| 2.10 | Tikus Putih | 50 |
| 2.11 | Kerangka Teoritis | 51 |

BAB 3 KERANGKA KONSEPTUAL DAN HIPOTESIS

| | | |
|-----|-------------------------------------|----|
| 3.1 | Kerangka Konseptual | 52 |
| 3.2 | Deskripsi Kerangka Konseptual | 53 |
| 3.3 | Hipotesis | 55 |

BAB 4 METODE PENELITIAN

| | | |
|-------|--|----|
| 4.1 | Rancangan Penelitian | 56 |
| 4.2 | Populasi, Sampel, Besar Sampel, dan Teknik Pengambilan Sampel..... | 57 |
| 4.2.1 | Populasi | 57 |
| 4.2.2 | Sampel | 57 |
| 4.2.3 | Besar sampel | 57 |
| 4.2.4 | Teknik pengambilan sampel..... | 58 |
| 4.3 | Variabel, Definisi Operasional Variabel, Prinsip Reaksi dan Ringkasan Cara Pengerjaan..... | 59 |
| 4.3.1 | Variabel penelitian | 59 |
| 4.3.2 | Definisi operasional variabel | 60 |
| 4.3.3 | Prinsip reaksi dan ringkasan cara pengerjaan..... | 62 |
| 4.4 | Alat dan Bahan Penelitian | 64 |
| 4.4.1 | Alat | 64 |
| 4.4.2 | Bahan | 64 |
| 4.5 | Tempat dan Waktu Penelitian | 65 |
| 4.5.1 | Tempat penelitian | 65 |
| 4.5.2 | Waktu penelitian | 65 |
| 4.6 | Prosedur Pengambilan dan Pengumpulan Data | 65 |
| 4.6.1 | Tahap persiapan hewan coba | 65 |
| 4.6.2 | Perhitungan dosis pemberian <i>Lactobacillus plantarum</i> | 66 |
| 4.6.3 | Tahap perlakuan | 67 |
| 4.6.4 | Pengambilan sampel darah..... | 68 |
| 4.6.5 | Cara pemeriksaan kadar LDL dan kolesterol total | 69 |

| | | |
|--|---|----|
| 4.6.6 | Cara pengukuran kadar interleukin-8 dan interleukin-10... | 69 |
| 4.6.7 | Pemusnahan..... | 69 |
| 4.7 | Analisis Data | 70 |
| 4.8 | Kerangka Operasional Penelitian | 71 |
| BAB 5 ANALISIS HASIL PENELITIAN | | |
| 5.1 | Model Hiperlipidemia..... | 72 |
| 5.2 | Pemberian <i>Lactobacillus plantarum</i> terhadap Kolesterol Total dan LDL..... | 73 |
| 5.3 | Pemberian <i>Lactobacillus plantarum</i> terhadap Kadar IL 8..... | 75 |
| 5.4 | Pemberian <i>Lactobacillus plantarum</i> terhadap Kadar IL 10..... | 76 |
| BAB 6 PEMBAHASAN | | |
| 6.1 | Model Hiperlipidemia..... | 78 |
| 6.2 | Pengaruh Pemberian <i>Lactobacillus plantarum</i> terhadap Kadar Kolesterol Total dan Kolesterol LDL..... | 79 |
| 6.3 | Pengaruh Pemberian <i>Lactobacillus plantarum</i> terhadap Kadar IL 8..... | 80 |
| 6.4 | Pengaruh Pemberian <i>Lactobacillus plantarum</i> terhadap Kadar IL 10..... | 83 |
| 6.5 | Keterbatasan Penelitian..... | 84 |
| BAB 7 KESIMPULAN DAN SARAN | | |
| 7.1 | Kesimpulan..... | 86 |
| 7.2 | Saran..... | 86 |
| DAFTAR PUSTAKA..... | | 87 |
| LAMPIRAN..... | | 98 |

DAFTAR TABEL

| Tabel | Halaman |
|---|---------|
| 2.1. Penyakit pada sindroma metabolik | 17 |
| 2.2 Komposisi diet standar..... | 19 |
| 4.1. Variabel yang diukur..... | 61 |
| 4.2. Komposisi diet tinggi lemak | 62 |
| 4.3 Konversi dosis antara berbagai species berdasarkan luas permukaan tubuh..... | 68 |
| 5.1 Hasil uji normalitas pada pembuatan model hiperlipidemia..... | 74 |
| 5.2 Deskripsi data kadar kolesterol total dan LDL..... | 74 |
| 5.3 Deskripsi data kadar kolesterol total setelah pemberian <i>Lactobacillus plantarum</i> | 75 |
| 5.4 Deskripsi data kolesterol LDL setelah pemberian <i>Lactobacillus plantarum</i> antara kelompok (K-) dan (K+)..... | 76 |
| 5.5 Deskripsi data kolesterol LDL setelah pemberian <i>Lactobacillus plantarum</i> antara kelompok (K+) dan (P1)..... | 76 |
| 5.6 Deskripsi data kolesterol LDL setelah pemberian <i>Lactobacillus plantarum</i> antara kelompok (K+) dan (P2)..... | 77 |
| 5.7 Deskripsi data kadar IL 8 setelah pemberian <i>L plantarum</i> | 77 |
| 5.8 Deskripsi data kadar IL 10 setelah pemberian <i>Lactobacillus plantarum</i> pada kelompok kontrol negatif (K-) dan kelompok kontrol positif (K+)..... | 78 |
| 5.9 Deskripsi data kadar IL 10 setelah pemberian <i>Lactobacillus plantarum</i> pada kelompok kontrol negatif (K-) dan kelompok perlakuan 1 (P1)..... | 78 |
| 5.10 Deskripsi data kadar IL 10 setelah pemberian <i>Lactobacillus plantarum</i> pada kelompok kontrol negatif (K-) dan kelompok perlakuan 2 (P2)..... | 79 |

DAFTAR GAMBAR

| Gambar | Halaman |
|--|---------|
| 2.1 Contoh komposisi taksonomi mikrobiota usus..... | 8 |
| 2.2 Jalur menghubungkan diet tinggi lemak, metabolisme endotoksemia dan penyakit kronis | 12 |
| 2.3 Dampak obesitas, sindroma metabolik, sistem kekebalan tubuh..... | 13 |
| 2.4 Bagian dari hati pada diet rendah lemak dan diet tinggi lemak yang diwarnai H&E..... | 15 |
| 2.5 Mekanisme berkembangnya <i>Enterobacteriaceae</i> yang diakibatkan peradangan..... | 21 |
| 2.6 Sekresi adipokin memicu peradangan kronis tingkat rendah pada jaringan adiposa (obesitas)..... | 24 |
| 2.7 Homeostasis dan gangguan usus..... | 26 |
| 2.8 Transportasi transeluler dan paraseluler | 28 |
| 2.9 Jalur pensinyalan IL 8 (pro-inflamasi)..... | 36 |
| 2.10 Strukur kimia asam empedu | 41 |
| 2.11 PPAR bertindak sebagai faktor transkripsi yang diaktifkan ligan | 43 |
| 2.12 Peran jalur pensinyalan PPAR γ | 44 |
| 2.13 Mekanisme utama aksi probiotik | 46 |
| 2.14 Modulasi mikrobial dari system kekebalan mukosa..... | 47 |
| 2.15 Kerangka teoritis | 51 |
| 3.1 Kerangka konseptual penelitian | 52 |
| 4.1 Rancangan penelitian | 56 |
| 4.2 Kerangka operasional..... | 71 |

DAFTAR SINGKATAN

| | |
|-----------------------|--|
| AHR | : <i>aryl hydrocarbon receptor also known as TICAM1</i> |
| AMP | : <i>antimicrobial peptide</i> |
| AMPK | : <i>AMP-activated protein kinase</i> |
| ANGPTL4/FIAF | : <i>angiopoietin-like protein 4</i> |
| AP 1 | : <i>adaptor protein 1</i> |
| Apo A-V | : <i>apolipoprotein A-V</i> |
| APRIL | : <i>a Proliferation-Inducing Ligand,</i> |
| ASP | : <i>acylation-stimulating protein</i> |
| AT | : <i>Adipose tissue</i> |
| AX | : <i>arabinoxylans.</i> |
| BAFF | : <i>B-Cell-Activating Factor</i> |
| BAT | : <i>brown adipose tissue</i> |
| BSH | : <i>bile salt hydrolase enzyme</i> |
| CCL2 | : <i>(MCP-1) : chemokines C-C motif chemokine 2</i> |
| CFU | : <i>colony-forming units</i> |
| CHOD-PAP | : <i>cholesterol oxidase-peroxidase aminoantypirin</i> |
| CLS | : <i>crown-like structures</i> |
| CM | : <i>chylomicron</i> |
| CVD | : <i>cardiovascular diseases</i> |
| CXCL1 | : <i>C-X-C motif chemokine 1</i> |
| ELISA | : <i>enzyme linked immunosorbent assay</i> |
| ERK | : <i>extracellular signal-regulated kinase</i> |
| FFA | : <i>free fatty acid</i> |
| FGF21 | : <i>fibroblast growth factor 21</i> |
| FXR | : <i>farnesoid X receptor (bile acid receptor)</i> |
| GLP | : <i>glucagon-like peptide</i> |
| GPR43 | : <i>G-coupled receptors protein 43</i> |
| HDL | : <i>high-density lipoprotein</i> |
| IEC | : <i>intestinal epithelial cells</i> |
| I κ B kinase | : <i>canonical IKK complex, the p38 family of MAPKs</i> |
| I κ B α | : <i>inhibitor of nuclear factor-kB</i> |
| IKKi | : <i>inducible protein kinase inhibitor of kB (IkB)</i> |
| IKK α | : <i>inhibitor of kappa-B kinase complex α</i> |
| IKK β | : <i>inhibitor of kappa-B kinase complex β</i> |
| IL-1,2,6,8,12 | : <i>interleukin 1,2,6,8,12</i> |
| ILC | : <i>innate lymphoid cell</i> |
| IRAK 4/1 | : <i>interleukin receptor associated kinase 4/1</i> |
| IRF 3 | : <i>interferon regulatory factor 3</i> |

| | |
|----------------|---|
| ITF | : <i>inulin-type fructans</i> |
| JNKs | : <i>c-Jun N-terminal kinases</i> |
| LBP | : <i>LPS binding protein</i> |
| LDL | : <i>low-density lipoprotein</i> |
| LPDC | : <i>lamina propria dendritikc cell</i> |
| LPL | : <i>lipoprotein lipase</i> |
| LPS | : <i>lipopolysaccharide</i> |
| MAPKs | : <i>mitogen-activated protein kinases</i> |
| MCP-1 | : <i>monocyte chemoattractant protein1, also known as CCL2</i> |
| MetS | : <i>metabolic syndrome</i> |
| MIF | : <i>macrophage migration inhibitory factor</i> |
| MUC | : <i>mucin glycoprotein</i> |
| MyD88 | : <i>myeloid differentiation primary response gene 88</i> |
| NAFLD | : <i>non alcoholic fatty liver disease</i> |
| NEMO | : <i>NF-kappa-B essential modulator also known as IKK-γ</i> |
| NF-kB | : <i>nuclear factor kappa B</i> |
| PAI-1 | : <i>plasminogen activator inhibitor-1</i> |
| PPAR α | : <i>peroxisome proliferator-activated receptor-α</i> |
| PPAR- γ | : <i>peroxisome proliferator-activated receptor-γ</i> |
| PPRE | : <i>PPAR response element</i> |
| PRRs | : <i>pattern recognition receptors</i> |
| PSA | : <i>polisakarida A</i> |
| PYY | : <i>peptide YY</i> |
| RBP4 | : <i>retinol binding protein 4</i> |
| RIP 1 | : <i>receptor interacting protein-1</i> |
| RXR α | : <i>retinoid \times receptor α</i> |
| SAA | : <i>serum amyloid A</i> |
| SCFA | : <i>short chain fatty acid</i> |
| SFB | : <i>segmented filamentous bacteria</i> |
| SFRP5 | : <i>secreted frizzled-related protein 5</i> |
| SREBP | : <i>sterol-regulatory-element-binding protein</i> |
| TAK 1 | : <i>transforming growth factor β (TGF-β)-activated kinase-1 also known as MAP3K7</i> |
| TANK | : <i>TRAF family member-associated NF-kB activator</i> |
| TBK 1 | : <i>TANK-binding kinase-1</i> |
| TG | : <i>triglyceride</i> |
| TGF- β | : <i>transforming growth factor β</i> |
| TIR | : <i>toll-Interleukin 1 receptor</i> |
| TIRAP | : <i>toll-interleukin 1 receptor adapter protein</i> |
| TLR 4 | : <i>toll-like receptor 4</i> |

| | |
|---------------|---|
| TNF- α | : <i>tumor necrosis factor alpha</i> |
| TRAF 6/3 | : <i>tumor necrosis factor (TNF)-receptor associated factor6/3</i> |
| TRAM | : <i>TRIF related adapter molecule</i> |
| TRIF | : <i>toll-interleukin receptor domain containing adaptor-inducing interferon-β</i> |
| UBC13 | : <i>ubiquitin-conjugating enzyme</i> |
| UEV1A | : <i>ubiquitin-conjugating enzyme E2 variant 1</i> |
| VLDL | : <i>very-low-density lipoprotein</i> |

DAFTAR LAMPIRAN

| Lampiran | Halaman |
|---|---------|
| 1 Uji etik penelitian | 98 |
| 2 Sertifikat hasil pengujian <i>Lactobacillus plantarum</i> | 99 |
| 3 Surat keterangan hewan coba..... | 100 |
| 4 Surat keterangan penelitian..... | 101 |
| 5 Tabel Konversi dosis antara berbagai <i>species</i> berdasarkan luas permukaan tubuh (Laurence <i>and</i> Bacharach, 1964)..... | 102 |
| 6 Hasil uji signifikansi..... | 102 |
| 7 Dokumentasi penelitian..... | 115 |